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Unilateral ureteral obstruction (UUO) is a well-characterized
hydronephrosis model exhibiting interstitial
inflammatory-cell infiltration and tubular dilatation followed
by tubulointerstitial fibrosis of the obstructed kidney. Our
recent report indicates that rapamycin is effective for 50% of
transplant recipients with chronic allograft nephropathy. In
this study, we investigate the effect of rapamycin on
UUO-induced renal fibrosis. UUO or sham-operated rats were
randomly assigned to rapamycin or vehicle and were killed
on days 7 and 14 after UUO or sham operation. Rapamycin
decreased cross-sectional and gross-morphology changes in
the obstructed kidney significantly. Rapamycin markedly
blunted the increase in weight of the obstructed kidney,
obstructed kidney length, and the obstructed/
non-obstructed kidney weight ratio (by 74.6, 42.8, and 61.6%
on day 14, respectively, all Po0.01). The scores for tubular
dilatation, interstitial volume, interstitial collagen deposition,
and a-smooth muscle actin (a-SMA) after UUO were
significantly reduced by rapamycin. Rapamycin also
decreased the number of infiltrative anti-ED1-positive cells
and the gene expression of transforming growth factor
(TGF)-b1 (84.8 and 80.2% on day 7) after UUO (both Po0.01).
By double immunostaining and Western analysis, rapamycin
blocked the TGF-b1-induced loss of E-cadherin expression
and de novo increase of the expression of a-SMA in a
dose-dependent manner. In conclusion, rapamycin
significantly attenuated tubulointerstitial damage in a
UUO-induced rat model of renal fibrosis, suggesting that
rapamycin may have the potential to delay the progression
of tubulointerstitial renal fibrosis.
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Renal tubulointerstitial fibrosis is a morphological hallmark
of chronic renal disease as well as a component of normal
aging in the kidney and of chronic renal allograft nephro-
pathy.1 Tubulointerstitial fibrosis is characterized by mixed
tubulointerstitial mononuclear cell infiltration, fibroblast
proliferation, and accumulation of extracellular matrix
proteins leading to tubular cell loss.1
The new anti-proliferative immunosuppressant, rapamy-
cin, is a macrocyclic lactone product of Streptomyces
hygroscopicus.2 Rapamycin reduces T-lymphocyte activation
at a later stage in the cell cycle by inhibiting the post-
interleukin-2 receptor mammalian target of rapamycin signal
transduction pathway. Rapamycin inhibits the translation of
cell cycle-regulating proteins, cyclin E, cyclin A-dependent
kinase p33cdk2 and p34cdc2, by signal blockade toward
p70S6 kinase.3
Recently, we reported that rapamycin effectively attenu-
ated progression of chronic allograft nephropathy in 50% of
kidney transplant recipients.4 Moreover, according to the
protocol biopsy findings from the Rapamune Maintenance
Regimen study, Mota et al.5 reported that withdrawing
cyclosporine from the rapamycin–cyclosporine–steroid regi-
men resulted in a significant decrease in the mean tubular
atrophy score and the chronic allograft damage score.
Rapamycin has been shown to reduce profibrotic gene
expression in both experimental and clinical settings.6,7
Additionally, rapamycin proved to have potent anti-prolif-
erative actions in the experimental models of bleomycin-
induced pulmonary fibrosis and carbon tetrachloride-induced
hepatic fibrosis in rats.8,9 However, whether rapamycin has an
anti-fibrotic effect on renal fibrosis deserves further study.
The experimental hydronephrosis model, unilateral ur-
eteral obstruction (UUO), is a widely used model for pro-
gressive renal fibrosis that is independent of hypertension or
systemic immune disease.10–14 The obstructed kidney after
UUO exhibits significant interstitial inflammatory cell
infiltration and tubulointerstitial fibrosis. In this present
study, we hypothesized that the administration of rapamycin
in vivo might attenuate renal tubulointerstitial fibrosis after
UUO.
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RESULTS
Animals did not differ in body weight during the study
period. The plasma levels of rapamycin in the UUO-
rapamycin 2 mg/kg/day group were similar to the sham-
operation groups (6.471.1 vs 6.271.3 ng/ml). However, the
mean plasma level of rapamycin in the UUO-rapamycin
1 mg/kg/day group was relatively low (2.970.8 ng/ml). No
obvious histological change or mortality was found in rats
with sham operation fed with rapamycin or vehicle.
When compared to the sham-operated kidney and
contralateral non-obstructed kidney, the left obstructed
kidney weight and length increased significantly after UUO
(Figure 1a and b). The ratio between obstructed and
contralateral non-obstructed kidney weight (obstructed/
non-obstructed) also increased after UUO (Figure 1c). When
compared to the sham-operated group, 2 mg/kg/day rapa-
mycin significantly attenuated the increase of obstructed
kidney weight by 61.8% on day 7 and 74.6% on day 14 (both
Po0.01, Figure 1a), whereas the reduction was lesser in 1 mg/
kg/day rapamycin groups (21.5% on day 7 and 43.8% on day
14). Besides, the increase of kidney length was reduced by
2 mg/kg/day rapamycin (59.2% on day 7 and 42.8% on day
14, both Po0.01, Figure 1b). The reduction was also very
significant in 1 mg/kg/day rapamycin groups (32.7% on day 7
and 28.2% on day 14, both Po0.01). The ratios of between
obstructed and contralateral non-obstructed kidney weight
were also significantly decreased by 2 mg/kg/day rapamycin
(68.4% on day 7 and 61.6% on day 14, both Po0.01, Figure
1c). Again, the efficacy was lesser in 1 mg/kg/day (36.7% on
day 7 and 33.6% on day 14). Moreover, the same effect was
found in the cross-section morphology of the obstructed
kidney (Figure 2).
Rapamycin attenuated the histological changes in the
obstructed kidney induced by UUO
Ligation of the ureter generated a model of renal interstitial
fibrosis characterized by tubular atrophy and interstitial
matrix deposition in the obstructed kidney, whereas no
histological change was found in the contralateral kidney.
Figure 3b showed a representative histological finding on day
7 of UUO. The obstructed kidney showed severe tubular
dilatation, tubular atrophy, and widened interstitial space
with a greater number of interstitial cells and infiltrating
leukocytes. These changes were observed in the whole cortex,
although the degree of severity was not homogeneously
distributed. The administration of rapamycin (2 mg/kg/day)
significantly attenuated the tubulointerstitial damage after
UUO (Figure 3c). The scores of tubular dilatation after UUO
were significantly reduced by 60% on day 7 and 35.9% on day
14 (from 28 to 11.2% and from 30.1 to 19.3%, respectively,
both Po0.01, Figure 4a). The effect of 1 mg/kg/day rapa-
mycin was not prominent (17.9% on day 7 and 16.6% on day
14). In contrast, there were no changes of the sham-operated
kidney and contralateral kidney, regardless of the use of
rapamycin (Figure 3a).
The interstitial volume of the obstructed kidney was
significantly (Po0.01) increased on day 7 after UUO as
compared to that of contralateral kidneys. The administra-
tion of 2 mg/kg/day rapamycin largely blunted the increase of
the score of interstitial volume by 72.4% on day 7 and by
32% on day 14 (from 29 to 8% and from 33.7 to 22.9%,
respectively, both Po0.01, Figure 4b). The effect of 1 mg/kg/
day rapamycin was not significant (27.9% on day 7 and
20.2% on day 14). However, the score of interstitial volume
of the contralateral kidney was 3.870.2% (similar to that of
the control kidney, 3.970.2%) and did not change with
rapamycin administration (Figure 3a).
The score of interstitial collagen deposition by sirius
staining showed similar results (Figure 4c). Figure 3e was a
representative picture showing that the interstitial collagen
deposition of the obstructed kidney was significantly
increased on day 7 after UUO as compared to that of
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Figure 1 | Rapamycin significantly blunted (a) the increase of
obstructed kidney weight, (b) the obstructed kidney length, and
(c) weight ratio of kidney (obstructed/non-obstructed) on days 7
and 14 after unilateral ureteral obstruction (UUO). þ þPo0.01
versus vehicle-treated rats with sham operation; **Po0.01 versus
vehicle-treated rats after the same day of UUO. N¼ 5 for each group.
The bar represents mean7s.e.m.
a b c d e
Figure 2 | Effect of rapamycin on unilateral ureteral obstruction
(UUO)-induced renal fibrosis in rats. (a–e) Representative photo-
graphs show the cross-section of the obstructed kidney, stained with
hematoxylin–eosin, at the same magnification of (a) vehicle-treated
control, (b) vehicle-treated rats on day 7 after UUO, (c) rapamycin
(2 mg/kg/day)-treated rats on day 7 after UUO, (d) vehicle-treated rats
on day 14 after UUO, (e) rapamycin (2 mg/kg/day)-treated rats on day
14 after UUO.
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contralateral kidneys. The 2 mg/kg/day rapamycin adminis-
tration significantly blunted the increase in the score of
interstitial collagen deposition of the obstructed kidney by
46.5% on day 7 and by 37% on day 14 (from 25.4 to 13.6%
and from 34.6 to 21.8%, respectively, both Po0.01, Figure
4c). Again, the effect of 1 mg/kg/day rapamycin was not
significant (13.3% on day 7 and 18.8% on day 14). The score
of interstitial collagen deposition of the contralateral kidney
was 0.670.1% (similar to that of the control kidney,
0.670.1%) and did not change with rapamycin (Figure 3d).
Rapamycin decreased the expression of a-smooth muscle
actin and collagen in the obstructed kidney induced by UUO
We next examined the effect of rapamycin on interstitial
myofibroblasts characterized by the expression of a-smooth
muscle actin (a-SMA). The a-SMA was essentially expressed
in vascular smooth muscle cells in Sprague–Dawley rats. This
contrasted with a high number of cells with a-SMA
expression surrounding the peritubular and periglomerular
spaces that developed in Sprague–Dawley rats after UUO
(Figure 3h). The 2 mg/kg/day rapamycin significantly re-
duced the score of a-SMA expression in cortical interstitium
of UUO rats by 33.1% on day 7 and by 31.8% on day 14
(from 25.4 to 17% and from 33.7 to 23%, respectively, both
Po0.01, Figure 4d). Again, the effect of 1 mg/kg/day
rapamycin was not significant (10.2% on day 7 and 11.6%
on day 14). The score of a-SMA expression of the
contralateral kidney was 0.670.3% (similar to that of the
control kidney, 0.670.2%) and did not change with
rapamycin (Figure 3g).
Western blot analyses of the kidney tissue extracts also
revealed that the expression of a-SMA in the obstructed
kidney was significantly increased in a time-dependent
manner (Figure 5). The administration of rapamycin
significantly attenuated the increase of a-SMA expression in
a dose-dependent manner (Figure 5).
Furthermore, we determined the amounts of collagen and
total protein content in the paraffin-embedded kidney tissue
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Figure 3 | Rapamycin attenuated the tubulointerstitial change
of the obstructed kidney on day 7 after unilateral ureteral
obstruction (UUO) by different kinds of staining. Representative
micrographs of (a, b, c) hematoxylin–eosin staining, (d, e, f) sirius
staining, (g, h, i) a-smooth muscle actin staining, (j, k, l) TGF-b1, and
(m, n, o) anti-ED1 cell staining in kidney tissue of (a, d, g, j, m) normal
and (c, f, i, l, o) UUO rats treated with 2 mg/kg/day rapamycin or
(b, e, h, k, n) vehicle. Original magnification  400.
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Figure 4 | Rapamycin attenuated the scores of tubulointerstitial
damage of the obstructed kidney on days 7 and 14 after
unilateral ureteral obstruction (UUO). The scores for (a) tubular
dilatation, (b) interstitial volume, (c) interstitial collagen deposition,
(d) a-smooth muscle actin expression, (e) collagen/total protein (mg/
mg), and (f) anti-ED1 positive cell of the obstructed kidney on days 7
and 14 after UUO. þ þPo0.01 versus vehicle-treated rats with sham
operation; **Po0.01 versus vehicle-treated rats after the same day of
UUO. N¼ 5 for each group. The bar represents mean7s.e.m.
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sections. Compared to the control kidney (12.470.8 mg/g),
the values were significantly higher (Po0.01) in the obstru-
cted kidney (24.971.1 mg/g on day 7 and 33.772.9 mg/g on
day 14). The 2 mg/kg/day rapamycin effectively reduced the
amounts of collagen by 30.5% on day 7 and by 27.6% on day
14 (17.371.6 and 24.472.0 mg/g, respectively, both Po0.01,
Figure 4e). However, the effect of 1 mg/kg/day rapamycin was
not significant (21.771.7 mg/g on day 7 and 28.270.5 mg/g
on day 14).
Rapamycin reduced the infiltration of monocyte/macrophage
in the obstructed kidney induced by UUO
The infiltration of ED-1-positive monocyte/macrophage was
present as reported previously (Figure 3n).15 Rapamycin
pretreatment resulted in an effective reduction in the number
of infiltrating ED-1-positive cells by 84.8% on day 7 and by
42.5% on day 14 (from 24.4 to 3.7% and from 30.8 to 17.7%,
respectively, both Po0.01, Figures 3o and 4f). However, the
1 mg/kg/day rapamycin also failed to attenuate the increase of
infiltrating ED-1-positive cells. Besides, the infiltration of
ED-1-positive cells in the contralateral kidney was not
significant, and rapamycin treatment had no additional effect
(Figure 3m).
Rapamycin reduced the expression of transforming growth
factor-b1 gene in the obstructed kidney induced by UUO
Rapamycin-treated rats showed significant reduction of the
tubulointerstitial fibrosis after UUO. We further examined
the gene expression of transforming growth factor (TGF)-b1
for the proliferation of fibroblasts implicated in the renal
fibrosis. The expression of TGF-b1 was not detected in the
non-obstructed kidney (Figure 3j). However, intensive anti-
TGF-b1 reactivity was detected in the glomeruli, vessels,
interstitial fibrotic tissues, and some anti-TGF-b1 immuno-
reactivity was observed in tubular epithelium in the
obstructed kidney induced by UUO (Figure 3k). On the
contrary, rapamycin treatment lowered the UUO-induced
expression of TGF-b1 in the obstructed kidney (Figure 3l).
Using Northern blot analyses of RNA, we found a significant
increase in the mRNA levels of TGF-b1 in Sprague–Dawley
rats after UUO (Figure 6a). The treatment of rapamycin
(2 mg/kg/day) remarkably attenuated the expression of TGF-
b1 gene by 80.2% on day 7 and by 29.9% on day 14 after
UUO (Po0.01, Figure 6b).
Rapamycin blocked the phenotypic transformation of tubular
epithelial cells into myofibroblastic appearance induced by
TGF-b1 in NRK52E cells
The current evidence from animal study indicated that
rapamycin attenuated cell proliferation and interstitial matrix
proteins deposition. We therefore examined the effect of
rapamycin on the phenotypic transformation of tubular
epithelial cells into myofibroblastic appearance induced by
TGF-b1 in NRK52E cells. The NRK52E cells displayed typical
cobblestone morphology of epithelial cells when grown in
culture (Figure 7a). TGF-b1 induced profound phenotypic
changes, with cells becoming elongated in shape, dissociating
from neighboring cells, and losing their cobblestone mono-
layer pattern (Figure 7b). TGF-b1 also induced a dose-
dependent increase in the expression of a-SMA in NRK52E
cells (data not shown). The ability of TGF-b1 to induce the
phenotypic transformation of NRK52E cells was largely
abolished by the addition of rapamycin (5 ng/ml) (Figure 7c).
Western blot analyses revealed that simultaneous incuba-
tion of rapamycin with TGF-b1 significantly attenuated the
de novo increase of the expression of a-SMA and restored the
loss of E-cadherin expression in a dose-dependent manner
(Figure 7d). On the other hand, the expression of E-cadherin
was also blunted by TGF-b1 in a dose-dependent manner.
Rapamycin also restored the decrease of the expression of
E-cadherin (Figure 7d). Taken together, these data clearly
suggested that rapamycin blocked the transformation from
tubular epithelial cells into myofibroblasts and prevented
subsequent interstitial matrix accumulation in vitro.
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Figure 5 | Western blot showed rapamycin attenuated the de
novo expression of a-smooth muscle actin (a-SMA) on days 7 and
14 after unilateral ureteral obstruction (UUO). The same blot was
stripped and reprobed with actin to confirm equal loading.
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Figure 6 | (a) Northern blot analysis showed that rapamycin
significantly attenuated the expression of TGF-b1 gene on days 7
and 14 after unilateral ureteral obstruction (UUO). (b) Graphs
illustrating the average ratio mRNA/18S rRNA densitometric values
for TGF-b1 from 3 different Northern blots performed in similar
conditions. þ þPo0.01 versus vehicle-treated rats with sham
operation; **Po0.01 versus vehicle-treated rats after the same day
of UUO. The bar represents mean7s.e.m.
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DISCUSSION
This study demonstrated, to our knowledge for the first time,
that rapamycin can attenuate renal fibrosis in rats with UUO.
Our observation on the effect of rapamycin in UUO is similar
to the clinical effect of rapamycin on chronic renal allograft
nephropathy.4,5 After UUO, consistent with other re-
ports,11–14 an obviously widened interstitial space accom-
panied by a greater number of interstitial cells and infiltrating
macrophages was noted (Figure 3). Collagen fibers were also
increased in the interstitial space, forming a fine network.
The tubular basement membrane was thickened in the area
where interstitial inflammation was more prominent. These
changes were observed in the whole cortex, although the
degree of severity was not homogeneously distributed.
Importantly, we found that the administration of rapamycin
significantly blunted tubulointerstitial damage and the
increase of collagen matrix induced by UUO.
Rapamycin, also known as sirolimus, is a triene macrolide
antibiotic, which demonstrates anti-fungal, anti-inflamma-
tory, anti-tumor, and potent immunosuppressive properties.
It is emerging as a foundation for long-term immunosup-
pressive therapy in renal transplantation. Through the unique
inhibition of a multifunctional serine-threonine kinase, the
mammalian target of rapamycin, rapamycin could regulate
the cell proliferation, differentiation, growth, survival, and
migration.16–19 Recently, it has been reported that rapamycin
decreased the cell proliferation in cystic and non-cystic
tubules and markedly inhibited renal enlargement and
cystogenesis, and prevented the loss of kidney function in
a rat model of polycystic kidney disease.20 Moreover, rapa-
mycin has also been shown to inhibit the cytotoxic and
inflammatory response in murine macrophage cell line21 and
in the rat model of experimental mesangial proliferative
glomerulonephritis.22 In this study, we also provide evidence
to support that rapamycin has remarkable anti-inflammatory
ability.
In addition to the result of the anti-inflammatory effect,
whether rapamycin has anti-fibrotic mechanism remains
speculative. Previous studies demonstrated that hepatocyte
growth factor and bone morphogenetic protein-7 inhibited
renal fibrosis primarily by inhibiting the transdifferentiation
of tubular epithelial cells into myofibroblasts.23,24 In this
study, we demonstrated that rapamycin attenuated the de
novo expression of a-SMA in the obstructed kidney tissue
extracts. In progressive renal fibrosis, TGF-b1 also plays a role
in the transdifferentiation from tubular epithelial cells to
a-SMA-positive myofibroblasts.25–30 By double immunos-
taining, we showed that the addition of rapamycin could
markedly attenuate the de novo increase of the expression of
a-SMA and restore the loss of E-cadherin expression induced
by TGF-b1 in NRK52E cells. This may contribute, in part, to
its effects on epithelial to myofibroblast transdifferentiation
as well as fibrosis.
In the rat model of UUO-induced renal fibrosis, the initial
inflammatory response and the increase in angiotensin II, in
turn, induce later upregulation of profibrotic substances.31,32
This led to irreversible steps in renal fibrosis. Consistent with
previous reports,33 the infiltration of mononuclear cells in
the vehicle-treated obstructed kidney increased gradually
after UUO. However, we found that the anti-inflammatory
effect of rapamycin is more prominent on day 7 than that on
day 14. Besides, the TGF-b1 expression in the obstructed
kidney is not entirely eliminated by rapamycin. These
findings could have resulted from consistent impacts on the
kidney tissue after prolonged ligation of the ureter. Thus, it is
reasonable that the efficacy of rapamycin on day 14 is not
better than that on day 7. This further suggests that tailored
treatment of renal fibrosis may be necessary during the
different stages of the disease.
In summary, interstitial renal fibrosis is a common final
pathway leading to end-stage renal failure, irrespective
of the nature of the initial renal injury. Our findings provide
in vivo and in vitro evidence that rapamycin signifi-
cantly attenuates tubulointerstitial damage in an experi-
mental model of renal tubulointerstitial fibrosis after UUO.
The overall effect of rapamycin in this model appears
to be both anti-inflammatory and anti-fibrotic. In view
of its protective effect on different mechanisms of pathogen-
esis in this UUO model, rapamycin might be useful as an
early therapeutic agent for progressive renal fibrosis in
humans.
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Figure 7 | Rapamycin attenuated the TGF-b1 induced loss of
E-cadherin expression and de novo expression of a-smooth
muscle actin (a-SMA) in NRK52E cells. Double immunostaining was
used to detect E-cadherin (brown) and a-SMA (red). (a) The confluent
NRK52E cells in control medium showed a typical E-cadherin (brown)
staining in tight junctions and no a-SMA expression. (b) Six days of
TGF-b1 (10 ng/ml) induced the de novo expression of a-SMA (brown)
and a loss of E-cadherin expression in cultured NRK52E cells. (c) The
addition of rapamycin (5 ng/ml) inhibited the change seen with
10 ng/ml TGF-b1. The number of a-SMA-positive cells was largely
reduced, while most of the cells remained expressed E-cadherin at
the tight junction. Original magnification  400. (d) Western blot
showed TGF-b1 induced the de novo expression of a-SMA and a loss
of E-cadherin expression, but rapamycin blunted the change in a
dose-dependent manner. The same blot was stripped and reprobed
with actin to confirm equal loading.
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MATERIALS AND METHODS
Animals
The studies were performed on male Sprague–Dawley rats
(200–230 g) obtained from the National Laboratory Animal Center
(Taipei, Taiwan). All experimental procedures were performed
according to the animal care and ethics legislation and were
approved by the Animal Care Committee of Taichung Veterans
General Hospital.
Experimental design
UUO was performed as described previously.11–14 In brief, under
intraperitoneal pentobarbital anesthesia, the left kidney and ureter
were exposed via a flank incision. The left ureter was ligated with 4-0
silk at two points and cut between the ligatures in order to prevent
retrograde urinary tract infection. Finally, the wound was closed in
layers. Sham animals underwent identical surgical procedures, but
the left ureter was simply manipulated.
The efficacy of rapamycin (Wyeth-Ayerst, Taipei, Taiwan) on
UUO-induced renal fibrosis was examined on the days 7 and 14. In
both experimental sets, the rats were divided into the same five
groups: (1) UUO-rapamycin 2 mg/kg/day, the rats underwent UUO
and were treated with rapamycin (2 mg/kg/day, N¼ 5); (2) UUO-
rapamycin 1 mg/kg/day, the rats underwent UUO and were treated
with rapamycin (1 mg/kg/day, N¼ 5); (3) UUO-vehicle, the animals
underwent UUO but were treated with vehicle (phosphate-buffered
saline) instead of rapamycin (N¼ 5); (4) Sham-rapamycin, five rats
underwent sham operations and were treated with rapamycin (2 mg/
kg/day); (5) Sham-vehicle, animals underwent sham operations and
were treated with vehicle (N¼ 5). All rats were killed under
pentobarbital anesthesia (50 mg/kg body weight, intraperitoneally)
on day 7 or day 14 after UUO. The whole-blood samples were
collected before harvesting. Laboratory parameters, including
complete blood count and biochemistry, were analyzed by standard
procedure to monitor the side effects of rapamycin. A high-
performance liquid chromatography-ultraviolet method was used to
measure the plasma level of rapamycin by the central laboratory of
Wyeth-Ayerst Pharmacy Company (Taiwan).
Morphometric and immunohistochemical analysis
Bilateral kidneys from each rat were fixed in 4% formalin in
phosphate-buffered saline and embedded in paraffin. Four micro-
meter sections were stained with hematoxylin/eosin to assess the
grade of tubulointerstitial damage. A standard point counting
method, modified from previous reports,12 was used to determine
the histological changes after UUO. Briefly, under high magnifica-
tion ( 400), 20 non-overlapping fields from each section of the
renal cortex were photographed. A grid containing 100 (10 10)
sampling points was superimposed on each photograph. Points
falling on glomerular structures or on large vessels were excluded
from the total count. The tubular dilatation score was determined by
the number of points overlying dilated tubular spaces and then
converted to a percentage. The staining scores of interstitial volume,
interstitial collagen deposition, and interstitial a-SMA expression
were assessed accordingly. The interstitial collagen deposition score
was determined by the sirius staining well established in our
laboratory, as described previously.15,34 The method used the
selective binding of sirius red F3BA to all collagen proteins and
fast green FCF to non-collagen proteins when both were dissolved in
aqueous saturated picric acid.
To evaluate infiltration of interstitial monocyte/macrophage,
rabbit polyclonal antibody against ED-1 (1:200; Serotec, Oxford,
UK) was applied as the primary reaction, followed by a second
reaction with biotin-labeled anti-rabbit IgG (Vector Laboratory,
Peterborough, UK). Finally, a 3,30-diaminobenzidine reaction
was performed on the section, using a kit (Dako, Carpinteria, CA,
USA), and hematoxylin was used as the counterstain. The number of
ED-1-positive cells was determined from 10 randomly chosen  400
fields within the same section of kidney from an individual
animal.13 The average number of ED-1-positive cells from five
separate rats was calculated.
All immuno-histochemical studies were performed on paraffin-
embedded sections as described previously.15,34,35 As a negative
control, the primary antibody was replaced with normal rabbit IgG,
without staining. The matrix score for a-SMA expression in the
renal cortical interstitium was determined by procedures in
accordance with previous reports.12 The monoclonal antibody
against human a-SMA (1:200; EPOS System, Dako) was used.
For the localization of TGF-b1 protein, rabbit anti-human TGF-b1
(1:50 dilution; Santa Cruz, CA, USA) was used as described
previously.23
Quantitative determination of collagen and total protein
The quantitative measurement of collagen and total protein content
in formalin-fixed, paraffin-embedded tissue sections was preformed
as described previously.34,36 Briefly, the method uses the selective
binding of sirius red F3BA to collagen protein and Fast-green FCF to
non-collagen protein when both are dissolved in aqueous saturated
picric acid. When the dye was eluted from tissue sections with
sodium hydroxide-methanol, the absorbances of 540 and 605 nm
were determined for sirius red F3BA and Fast green FCF-binding
proteins. The absorbances provided a relative measurement of
collagen/total protein (mg/mg) quantity.34,36 Because the determina-
tion of collagen was relative to the concentration of protein per
milligram in each tissue section, the thickness or the area of
histological preparation was not a significant factor.
Western blot analysis
The expression of E-cadherin and a-SMA proteins in cell lysates and
kidney tissue was analyzed by Western blotting as described
previously.25,37,38 Briefly, cell lysates (20mg protein) were separated
on 10% sodium dodecyl sulfate-polyacrylamide gels. The proteins
were electroblotted onto a nitrocellulose membrane (Amersham,
Piscatway, NJ, USA). Filters were incubated overnight at 41C with
antibodies directed against the E-cadherin (C37020; Transduction,
Lexington, KY, USA), or a-SMA (Dako), or actin (Santa Cruz) and
then incubated with secondary antibody. Three experiments were
performed.
Northern blot analysis
From each animal, aliquot of both kidneys were snap frozen in
liquid nitrogen and stored at 801C as described previously.37 Total
RNA was separated on 1.0% agarose gels and subsequently
transferred to nylon membranes. The membranes were hybridized
with digoxigenin-labeled RNA probes and then developed by CSPD
(Roche, Mannheim, Germany). The amount of expressed RNA was
quantitated by the Molecular Imager (Bio-Rad, Hercules, CA, USA)
as described previously.23,37 Results were expressed as mRNA/18S
rRNA relative optical density ratios to correct for any RNA-loading
inequality. We have assessed that 18S rRNA control is not saturated
and that we work in the lineal range or the relation intensity of the
band/mRNA amount. For the synthesis of rat TGF-b1 RNA probe, a
cDNA fragment was first generated by reverse transcription-
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polymerase chain reaction from glomerular RNA of anti-thy1
injected rats, using the specific primer as reported previously.39
Cell culture and treatment
The normal rat kidney epithelial cell line (NRK52E) was maintained
in Dulbecco’s modified Eagle’s medium (Sigma, St Louis, MO, USA)
supplement with 1% fetal calf serum as described previously.25 To
evaluate the inhibitory effect of rapamycin on the phenotypic
transformation of tubular epithelial cells into myofibroblastic
appearance induced by TGF-b1,25 NRK52E cells were cultured for
6 days in the presence of 0, 1, 10, 50 ng/ml recombinant human
TGF-b1 (Promega, Madison, WI, USA) with or without 1, or 5, or
10 ng/ml rapamycin (Sigma). During these experiments, the media
were changed after three days, at which point fresh TGF-b1 and/or
rapamycin were added.
Double immunostaining of NRK52E cells
The NRK52E cells were cultured in four chamber glass slides with or
without collagen coating in the presence or absence of TGF-b1, and
were stained with monoclonal antibodies to a-SMA (Dako) or
E-cadherin (C37020; Transduction) using DAKO EnVision double-
stain system according to the manufacturer’s instructions
(Dako).25,40 Cells were incubated with the anti-E-cadherin antibody
(Transduction) for one hour and then incubated sequentially with
peroxidase-conjugated goat antimouse IgG and peroxidase-conju-
gated anti-peroxidase complexes, followed by development with
diaminobenzidine to produce a brown color. Sections were then
preincubated again and incubated with monoclonal antibody
directed against the a-SMA. Finally, sections were developed with
the Fast Red substrate chromogen, which results in a red-colored
precipitate at the antigen site.
Statistics
All data were expressed as mean7s.e.m. For Northern and Western
blot analyses, quantitation was performed by scanning and deter-
mination of the intensity of signals. Statistical calculations were
performed using the SPSS software for statistical analysis (SPSS,
Chicago, IL, USA). One-way analysis of variance and multiple
comparison tests were used to determine the statistical significance.
Statistical significance was defined as P-value less than 0.05.
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